Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs

Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs

Projected increases of cancer-attributable health-care costs, accompanied by staff shortages, will impose future economic and operational challenges on national health-care systems. Herein, we highlight a series of clinical and health economic rationales in support of publicly funded clinical trial...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Clinical oncology Vol. 21; no. 2; pp. 81 - 82
Main Authors: Theilgaard-Mönch, Kim, Ehlers, Lars Holger
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 01-02-2024
Nature Publishing Group
Subjects:
4014/4045
692/4028/67/1059/153
Biomarkers
Cancer therapies
Clinical medicine
Clinical trials
Comment
Cost analysis
Cost control
Cost reduction
Drug dosages
Health care expenditures
Health economics
Hospitals
Humans
Labor shortages
Medical Oncology
Medicine
Medicine & Public Health
Neoplasms - drug therapy
Oncology
Optimization
Patients
Pharmaceutical industry
Quality of Life
Reimbursement
Scholarships & fellowships
Toxicity
Workforce planning
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Projected increases of cancer-attributable health-care costs, accompanied by staff shortages, will impose future economic and operational challenges on national health-care systems. Herein, we highlight a series of clinical and health economic rationales in support of publicly funded clinical trial teams that conduct real-world dose-reduction trials aiming for adjustment of cancer drug label doses to reduce not only the financial burden on payers, but also the toxicity burden on patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1759-4774
1759-4782
DOI:10.1038/s41571-023-00831-5